Palatin Technologies Inc
NYSE American:PTN

  • LAST PRICE
    1.1400
  • TODAY'S CHANGE (%)
    0.0100 (0.8850%)
  • Bid / Lots
    1.1200/ 5
  • Ask / Lots
    1.1400/ 1
  • Open / Previous Close
    1.1400 / 1.1300
  • Day Range
    1.1000
    1.2200
  • 52 Week Range
    0.6800
    5.6500
  • Volume
    138,145

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 25, 2024

  • Nov 14, 2024

      Show headlines and story abstract

    • 7:30AM ET on Thursday Nov 14, 2024 by PR Newswire
      Companies Mentioned: PTN

      -- Obesity programs:

      -- Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates

      -- Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plusGLP-1/GIP dual agonist tirzepatide

    • 7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: PTN
      common share $ (0.39) $ (0.43) =================================== =============================== Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share 19,845,106 12,170,699 =================================== =============================== PALATIN TECHNOLOGIES, INC. and Subsidiary Consolidated Balance Sheets (unaudited) September 30, 2024 June 30, 2024 ----------------------------- ----------------- ASSETS Current assets: Cash and cash equivalents $ 2,384,214 $ 9,527,396 Prepaid expenses and other current assets 228,435 242,272 ----------------------------- ----------------- Total current assets 2,612,649 9,769,668 Property and equipment, net 307,571 388,361 Right-of-use assets - operating leases 438,123 527,321 Other assets 56,916 56,916 ----------------------------- ----------------- Total assets $ 3,415,259 $ 10,742,266 ============================= ================= LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY Current liabilities: Accounts payable $ 3,949,028 $ 4,101,929 Accrued expenses 4,573,292 4,185,046 Short-term operating lease liabilities 319,520 380,542 Short-term finance lease liabilities 18,527 46,014 Other current liabilities 1,001,350 944,150 ----------------------------- ----------------- Total current liabilities 9,861,717 9,657,681 Long-term operating lease liabilities 132,447 163,782 Other long-term liabilities 1,106,700 1,032,300 Total liabilities 11,100,864 10,853,763 ----------------------------- ----------------- Stockholders' deficiency: Preferred stock of $0.01 par value -- authorized 10,000,000 shares: shares issued and outstanding designated as follows: Series A Convertible: authorized 4,030 shares as of September 30, 2024: issued and outstanding 4,030 shares as of September 30, 2024 and June 30, 2024 40 40 Common stock of $0.01 par value -- authorized 300,000,000 shares: issued and outstanding 19,548,167 shares as of September 30, 2024 and 17,926,640 shares as of June 30, 2024 195,481 179,266 Additional paid-in capital 441,709,073 441,475,747 Accumulated deficit (449,590,199) (441,766,550) ----------------------------- ----------------- Total stockholders' deficiency (7,685,605) (111,497) ----------------------------- ----------------- Total liabilities and stockholders' deficiency $ 3,415,259 $ 10,742,266 ============================= =================

Peers Headlines